Integer Holdings enters the week with fresh bullish momentum from the Street — but short sellers are quietly adding to positions at the same time.
Oppenheimer initiated an Outperform rating on Integer this morning with a $115 price target. That's 35% above Tuesday's close of $84.98. The upgrade lands just two weeks after a Q1 print that was well-received: the stock gained 0.4% the day earnings dropped on April 30 and followed through with a 5.1% gain over the next five sessions. The timing is notable — Oppenheimer is moving to the sidelines just as short interest has started climbing again.
Short interest has been building steadily. At 12% of the free float as of May 12, it has risen roughly a full percentage point from the late-April low near 11.1%. That represents about 1.9% growth week-on-week, with short shares up 5.3% over the past month. Despite the rising short count, the borrow market itself is nowhere near distressed. Cost to borrow is running at just 0.37% — down 26% over the past month and among the cheapest it has been all year. Availability in the lending pool remains comfortable, with only around 15% of available borrow currently in use against a 52-week peak of 20.6%. That picture says short sellers can add freely — there is no squeeze dynamic building here. Options lean slightly defensive, with the put/call ratio at 0.95, near its 52-week high of 0.9523 and above its 20-day average of 0.87, though the z-score of 0.54 is not extreme. Taken together, positioning is cautious but not crowded.
The Street is split. Oppenheimer's upgrade to Outperform at $115 stands in contrast to Citigroup, which trimmed its target to $89 on May 1 while maintaining Neutral. Piper Sandler is more constructive — it reiterated Overweight and raised its target to $97 from $87 on the same day, post-earnings. The consensus is now evenly divided between four Buy ratings and four Hold ratings, with a mean target of $97.22 — roughly 14% above current levels. The bull case rests on Integer's exposure to high-growth cardiovascular and vascular segments, its compounding inorganic strategy, and leveraged EPS upside. Bears flag acquisition pricing risk and near-term softness in electrophysiology and neuromodulation. The PE sits at 13.4x, with EV/EBITDA at 10.5x — the latter up slightly over the past 30 days, suggesting modest multiple expansion even as the stock has drifted flat to down over the period.
One institutional note worth watching: Invesco filed a Schedule 13G this week, now holding 5.3% of shares — a position that grew by more than 636,000 shares in the most recent reporting period. MFS and Manulife also added meaningfully in their last filings. On the insider side, recent activity has been routine: the CFO received an award and sold a small tranche on May 8 at $88.12. Net insider activity over 90 days is modestly positive in shares but reflects award-grant cycles more than conviction buying.
The ORTEX short score is steady at 57.3 — it has eased slightly from a recent high of 58.9 hit around the April 30 earnings date, suggesting the post-print period saw modest short-side retreat before the current rebuilding trend. Peer GMED had a rough week, off 15.4%, while ICUI gained 5.3% and STE rose 4.5%. ITGR's flat-to-down week looks relatively resilient in that context. The question heading into the summer is whether the Oppenheimer upgrade catalyses fresh institutional interest, or whether the steady drift higher in short interest signals that sceptics see the post-earnings rally as a ceiling rather than a floor.
See the live data behind this article on ORTEX.
Open ITGR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
